Keros Therapeutics KROS Cash Flow Statement (2019-2026)

NASDAQ KROS
$11.37 -0.03 (-0.26%)
As of: Oct 21, 2026 · 10:27 AM EDT
Reported Financials

Keros Therapeutics Quarterly Cash Flow Statement

Periods 29 quarters
Latest Jun 2026

Keros Therapeutics cash flow statement data for the quarter ended Jun 2026. This cash flow statement covers 29 quarters of results from Mar 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Jun2026
Operating Activities
Net Income
-15.62M-20.30M-6.94M-24.19M-27.27M-23.51M-29.72M-35.80M-37.51M-39.44M-40.24M-43.11M-45.26M-52.96M-46.03M148.45M-30.70M-7.28M-23.46M-28.71M
Depreciation and DepletionDep. & Depletion
0.09M0.10M0.10M0.11M0.31M0.13M0.13M0.17M0.19M0.21M0.25M0.28M0.31M0.31M0.33M0.34M0.37M0.40M0.40M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF)Dep. & Amort.
0.09M0.10M0.10M0.11M0.31M0.13M0.13M0.17M0.19M0.21M0.25M0.28M0.31M0.31M0.33M0.34M0.37M0.40M0.40M
Share-based CompensationStock Comp.
2.85M3.08M3.30M4.39M4.79M4.75M4.75M5.69M7.04M8.71M7.32M8.07M8.79M8.82M9.20M8.86M8.54M3.99M7.31M
Gains from Sales and DivestituresGains Divest
-0.03M-0.01M0.00M0.00M0.00M
Other non-cash itemsOther Non-Cash
0.10M0.12M0.20M0.20M0.21M0.21M0.32M0.52M0.35M0.34M0.34M0.34M0.35M0.56M0.57M0.58M0.60M0.61M0.62M
Change in Working Capital
Change in ReceivablesChange Receivables
0.10M-0.10M18.00M-18.00M0.14M0.08M-0.22M0.38M2.35M14.55M-1.48M-12.32M0.08M
Change in Account PayablesChange Payables
-1.64M1.44M0.82M-0.67M4.66M-4.99M0.60M1.32M-0.57M-0.18M1.04M0.02M1.61M-1.59M-0.29M2.02M-1.37M-2.96M-0.70M
Change in Accured ExpensesChange Accured Exp.
0.20M1.65M-0.10M0.36M-0.58M1.28M4.26M-1.98M1.17M0.27M5.79M-5.35M0.90M8.71M-1.30M-3.58M2.67M-4.80M-4.43M
Change in TaxesChange Taxes
10.04M-3.72M-2.17M-6.40M
Change in Other Operating AssetsOther Assets Change
3.43M1.23M-2.04M-0.76M4.10M1.29M0.27M4.07M1.49M4.26M-0.06M4.48M6.39M-6.36M5.72M-6.14M4.64M-4.43M-0.14M
Change in Other Operating LiabilitiesOther Liabilities Change
-0.12M0.19M-0.02M-0.40M-0.61M1.01M3.31M-2.38M-0.77M
Other Working Capital ChangesOther WC Changes
-3.55M-1.04M2.02M0.36M-4.71M-0.28M-0.27M-4.07M-1.49M-4.26M0.06M-4.48M-6.39M6.36M-5.72M9.44M-7.02M3.66M0.14M
Cash from OperationsCash from Ops.
-17.64M-14.44M-19.57M-1.43M-22.59M-24.60M-21.44M-34.24M-30.83M-33.98M-25.46M-44.56M-39.80M-30.50M-46.01M161.17M-29.62M3.25M-27.29M
Investing Activities
Capital ExpendituresCapex
0.51M0.15M0.16M0.15M0.57M0.18M0.35M1.06M0.31M0.55M0.54M0.95M0.31M0.39M0.29M0.57M0.72M0.13M0.13M
Change in Property, Plant and EquipmentChange in PP&E
-0.51M-0.15M-0.16M-0.15M-0.57M-0.18M-0.35M-1.06M-0.31M-0.55M-0.54M-0.95M-0.31M-0.39M-0.29M-0.57M-0.72M-0.13M-0.13M
Cash from Investing ActivitiesCash from Investing
-0.51M-0.15M-0.16M-0.15M-0.57M-0.18M-0.35M-1.06M-0.31M-0.55M-0.54M-0.95M-0.31M-0.39M-0.29M-0.57M-0.72M-0.13M-0.13M
Financing Activities
Change in Capital Stock
Common Stock IssuedStock Issued
0.06M0.04M0.25M0.12M10.19M48.58M-58.08M107.68M-105.57M0.31M0.80M5.72M2.97M1.01M2.45M0.00M0.02M0.14M0.13M
Net Shares Issued and RepurchasedNet Shares Issued
0.06M0.04M0.25M0.12M10.19M48.58M-58.08M107.68M-105.57M0.31M0.80M5.72M2.97M1.01M2.45M0.00M0.02M0.14M0.13M
Net Preferred Shares Issued and RepurchasedNet Pref. Shares Issued
Net Equity Issued and RepurchasedNet Equity Issued
0.06M0.04M0.25M0.12M10.19M48.58M-58.08M107.68M-105.57M0.31M0.80M5.72M2.97M1.01M2.45M0.00M0.02M0.14M0.13M
Other financing activitiesOther financing
-0.09M-0.09M-0.26M-0.02M-0.17M0.14M
Cash from Financing ActivitiesCash from Financing
0.06M0.04M28.42M0.12M10.19M48.58M61.42M107.68M1.74M0.28M69.25M156.80M3.53M155.94M75.54M0.00M0.02M0.14M-378.63M
Additional items
Change in Cash
-18.09M-14.55M8.69M-1.46M-12.97M23.81M39.62M72.38M-29.40M-34.25M43.25M111.30M-36.58M125.06M29.25M160.61M-30.33M3.26M-406.06M
Ending Cash Balance
237.23M222.68M231.37M229.91M216.95M240.75M280.38M352.76M323.35M289.11M332.36M443.66M407.08M532.13M561.38M721.99M691.66M694.92M288.86M259.06M
Free Cash FlowFCF
-18.15M-14.59M-19.72M-1.57M-23.16M-24.78M-21.79M-35.30M-31.14M-34.53M-26.00M-45.51M-40.11M-30.89M-46.30M160.61M-30.34M3.12M-27.43M
Net Cash FlowNCF
-18.09M-14.55M8.69M-1.46M-12.97M23.81M39.62M72.38M-29.40M-34.25M43.25M111.30M-36.58M125.06M29.25M160.61M-30.33M3.26M-406.06M

Keros Therapeutics Cash Flow Statement API

Pull Keros Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=KROS&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY